http://www.ama-assn.org/sci-pubs/journals/most/recent/issues/inte/letter_4.htm

Editor’s Correspondence - September 13, 1999

 

Herbal Medicinals: Selected Clinical Considerations, Focusing on Known or Potential Drug-Herb Interactions

The issue of herb-drug interactions is an important one for clinicians.  However, the recent article by Miller[1] on this subject contains a number of errors and unsubstantiated statements.

The claim that Echinacea is hepatotoxic is unreferenced, presumably because there are no reports of this in the literature.

The unreferenced statement that ginkgo should be avoided in patients with epilepsy is not substantiated. The statement that ginkgo toxin is found in both leaf and seed is true but misleading. Ginkgo seeds, which are eaten on special occasions in Asia, contain 4’-O-methylpyridoxine, an anti-vitamin B6 neurotoxin. Boiling inactivates 99% of this toxin. However, during food shortages in China and Japan, overconsumption of ginkgo seeds resulted in a syndrome called gin-nan sitotoxism, with a 27% mortality rate.[2]

Ginkgo leaf extracts, however, are used therapeutically in the West; according to the author’s own citation, the leaves of ginkgo contain only tiny quantities of 4’-O-methylpyridoxine.[2] Ginkgo leaf extracts have not been shown to have toxic effects in animals or humans.

Both adverse effects attributed to Ginkgo biloba were probably drug interactions. The patient who developed spontaneous hyphema while taking ginkgo was also taking aspirin,[3] and the patient who developed spontaneous bilateral subdural hematomas was also taking acetaminophen and ergotamine/caffeine at the time of diagnosis.[4] The concurrent use of these drugs should have been noted. (Ginkgo alone has been associated with 1 case of subarachnoid hemorrhage[5] and 1 case of subdural hemorrhage,[6] but these cases were not referenced in this article.)

There is no reported association between kava and coma. It is true that the letter cited for this statement is misleadingly titled “Coma From the Health Food Store: Interaction Between Kava and Alprazolam,”[7] but the letter reports only lethargy and disorientation in this patient, not unconsciousness.

Statements in the story of the androgenized baby are not supported by the references. The original case report, not cited in the article, described a case of neonatal androgenization attributed to the maternal use of a product called Siberian ginseng (Eleutherococcus senticosus),[8] not, as stated in the article by Miller, “ginseng,” which is the unrelated Panax genus. The letters cited for the statement that “neonatal androgenization secondary to ginseng has been debated in the literature in cases in which maternal use of ginseng was identified as the cause of androgenization of the child”[9,10] actually debated only whether the product in the preceding case report should have been analyzed to determine whether it contained Siberian ginseng. In fact, a subsequent analysis of the preparation (not referenced) revealed that the preparation was devoid of Siberian ginseng but appeared to contain Periploca sepium, also called Chinese silk vine.[11] The reference[12] cited for the statement that “others contend the entity in

question was in fact a botanically different species, Siberian ginseng” is wrong. The reference actually only mentions the analysis that unmasked the purported Siberian ginseng as Periploca as background to an animal experiment that tested the androgenic qualities of Periploca.

The author conflates the uses and risks of borage leaves with borage seed oil; these are not interchangeable entities. It is borage seed oil, not (as stated) borage or borage oil (both leaf products), that is used as an alternative to evening primrose oil. It is only borage leaves, however, not borage seed oil, that contain significant levels of toxic pyrrolizidine alkaloids. (Although small amounts of pyrrolizidine alkaloids have been isolated from the seeds, borage seed oil has been found to be devoid of pyrrolizidine alkaloids.[13])

The statement concerning garlic that “several practitioners have noted elevated international normalized ratios (INR) and prothrombin times in patients previously stabilized while taking warfarin,” is not only unreferenced but does not fit with what we know about the anticoagulant effects of this herb. Garlic prevents platelet aggregation[14,15] and thus would be expected to alter bleeding times, not international normalized ratios or prothrombin times.

The caution against combining phytoestrogens with pharmaceutical estrogens because of possible estrogen excess is overstated. The strongest phytoestrogen is about 0.1% as potent as estradiol in binding assays.[16]

Adriane Fugh-Berman, MD

Department of Health Care Sciences

George Washington University School of Medicine

2150 Pennsylvania Ave NW

Suite 2B-417

Washington, DC 20037

 

References

1.  Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med.  1998;158:2200-2211.

2.  Arenz A, Klein M, Fiehe K, et al. Occurrence of neurotoxic 4’-O-methylpyridoxine in Ginkgo biloba leaves, Ginkgo medications and Japanese Ginkgo food. Planta Med. 1996;62:548-551.

3.  Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med. 1997;336:1108.

4.  Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996;46:1775-1776.

5.  Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba [letter].

Lancet. 1998;352:36.

6.  Gilbert GJ. Ginkgo biloba [commentary]. Neurology. 1997;48:1137.

7.  Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam [letter]. Ann Intern Med. 1996;12:940-941.

8.  Koren G, Randor S, Martin S, Danneman D. Maternal ginseng use associated with neonatal androgenization [letter]. JAMA. 1990;264:2866.

9.  Awang DVC. Maternal use of ginseng and neonatal androgenization [letter].JAMA. 1991;265:1828.

10. Koren G. Maternal use of ginseng and neonatal androgenization [reply].JAMA. 1991;265:1828.

11. Awang DVC. Maternal use of ginseng and neonatal androgenization [letter]. JAMA. 1991;266:363.

12. Waller DP, Martin AM, Farnsworth NR, Awang DVC. Lack of androgenicity of Siberian ginseng [letter]. JAMA. 1992;267:2329.

13. De Smet PAGM. Borago officinalis. In: De Smet PAGM, ed. Adverse Effects of Herbal Drugs, Volume II. Berlin, Germany: Springer-Verlag; 1993.

14. Kiesewetter H, Jung EM, Mrowietz C, et al. Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischemic attack. Eur J Clin Pharmacol. 1993;45:333-336.

15. Das I, Khan NS, Sooranna SR. Potent activation of nitric oxide synthase by garlic: a basis for its therapeutic applications. Curr Med Res Opin.  1995;13:257-263.

16. Knight DC, Eden JA. A review of the clinical effect of phytoestrogens.

Obstet Gynecol. 1996;87:897-904.

(Arch Intern Med. 1999;159:1957-1958)

 

 

 

In reply

Rosenblatt and Mindel[1] reported spontaneous hyphema in a 70-year-old man 1 week after he began ingesting Ginkgo biloba (40 mg twice daily). The patient had taken aspirin (325 mg/d) for 3 years without incident; hence, the authors felt that a temporal relationship strongly implicated ginkgo. I agree. Rowin and Lewis[2] have also reported spontaneous bilateral subdural hematomas associated with long-term G biloba use. They acknowledged that their patient had taken acetaminophen and had a very brief trial of ergotamine/caffeine tablets. However, given the lack of a temporal relationship and the fact that acetaminophen, ergotamine, and caffeine have not been shown to be associated with subdural hematomas, Rowin and Lewis implicated G biloba. Furthermore, the patient’s bleeding time improved following discontinuation of G biloba. Again, I agree with their conclusions. Yet another report was recently published describing a 61-year-old man who developed subarachnoid hemorrhage after ingesting G biloba (40 mg 3 or 4 times daily).[3] He was not taking any other medications.

Ginkgo toxin (4’-O-methylpyridoxine) has been characterized as a neurotoxic anti-vitamin B6 compound that Arenz et al[4] found “present in Ginkgo medications and ...detectable in homeopathic preparations.” Ginkgo toxin is more typically found in seeds.[5] Arenz et al, however, found it present in both seeds and leaves, with the highest amount derived from the tree in late July and early August.[4] In addition, as Fugh-Berman points out, contamination is a problem with many herbal medicinals. I believe it ill-advised to subject patients to the effects of a known neurotoxin, especially prone patients (eg, those with epilepsy), unless we can assure them that their ginkgo product does not contain this neurotoxin.

Almeida and Grimsley[6] describe a 54-year-old man who was hospitalized in a lethargic and disoriented state following ingestion of kava and alprazolam.  In the title of their letter, the authors refer to this state as a “coma”; in the text, they refer to the patient as being “semicomatose.” I defer to Almeida and Grimsley, who actually saw this patient, as to what his actual state was. Regardless of the term used, it would appear that an interaction exists and concomitant use should be avoided.

Ginseng is an herbal entity that historically has had reports of contamination and considerable variation in content. In my article, I alerted readers to the controversy and the contamination issue regarding neonatal androgenization associated with ginseng. I correctly cited the letters and commentaries in which this debate was argued, and I also noted that Siberian ginseng did not cause androgenization. Awang[7] subsequently conducted a mass spectrometric analysis of the indicted extracts, finding 4-methoxysalicyladehyde, consistent with Periploca sepium, also referred to as Chinese silk vine. I thank Fugh-Berman for pointing this out. It not only highlights the problem with products labeled as containing ginseng but further exemplifies the mislabeling and contamination issues we are facing with herbal products.

In regard to borage, I refer Fugh-Berman to reference 115 in my original article.[8] Newall et al note that evening primrose oil should be used cautiously in patients with epilepsy and make a similar recommendation for borage oil. I did not refer to borage leaves, as Fugh-Berman alleges.  Fugh-Berman correctly notes the distinction between borage seed oil and borage leaves.

I noted garlic’s effect on platelets in my original article, which of course would affect bleeding times and not international normalized ratios or prothrombin times. This provides an example of why we cannot assume we know everything about herbs. Clinical experience, when we are vigilant to inquire about herb use, teaches us otherwise. The lesson here is to acknowledge that much more study is needed.

I do not believe concomitant use of phytoestrogens with estrogen replacement therapy is well advised. One must first question why one would want to take these 2 products together for this indication. Secondly, given that the content of the herbal product may be in question (eg, mislabeling, contamination), it again does not seem rational to combine therapies and incur unnecessary risk and expense.

In my article, I noted that the risk that Echinacea will cause hepatotoxicity is very low because of medicinal chemistry considerations.  Fugh-Berman elected to ignore this sentence. Traces (0.006%) of the pyrrolizidine alkaloids (tussilagine and isotussilagine) have been found in Echinacea angustifolia and Echinacea purpurea, but these lack the 1,2-unsaturated necine ring system associated with hepatotoxicity; hence, this source characterized Echinacea-induced hepatotoxicity as unlikely.[9] The absence of this 1,2-unsaturated necine ring system was noted in the original article.

I commend the American Medical Association and the ARCHIVES specifically for their willingness to address alternative medicine and herbal medicinals.  They no doubt did so realizing that reactions would be varied.

Open debate and the exchange of information and ideas are the hallmarks of scholarly endeavors. This exchange needs to be conducted in a professional, objective, and respectful manner so that scholars and clinicians with expertise in herbal medicinals can bring their knowledge to bear for the benefit of patient care. It is hoped that with a thoughtful discourse and exchange the defining boundaries of herb use can be ascertained as they are for other medicinal interventions. With such a scientific approach, herbal medicinals can assume a safe and efficacious position among therapies offered to patients.

Lucinda G. Miller, PharmD, BCPS

Editor, Journal of Herbal Pharmacotherapy

Amarillo, Tex

 

Dr Miller currently serves on an advisory board to Warner-Lambert Co, Morris Plains, NJ.

References

1.  Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med. 1997;336:1108.

2.  Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996;46:1775-1776.

3.  Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba [letter].

Lancet. 1998;352:36.

4.  Arenz A, Klein M, Fiehe K, et al. Occurrence of neurotoxic 4’-O-methylpridoxine in Ginkgo biloba leaves, Ginkgo medications and Japanese Ginkgo food. Planta Med. 1996;62:548-551.

5.  Newall CA, Anderson LA, Phillipson ID. Ginkgo monograph. In: Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1996:138-140.

6.  Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125:940-941.

7.  Awang DVC. Maternal use of ginseng and neonatal androgenization [letter].JAMA. 1991;266:363.

8.  Newall CA, Anderson LA, Phillipson ID. Borage monograph. In: Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1996:49.

9.  Bisset NG, ed. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis. Stuttgart, Germany: Medpharm Scientific Publishers; 1994:182-183.(Arch Intern Med. 1999;159:1958-1959)